Thursday, Apr 22 2021 | Time 22:54 Hrs(IST)
image
  • Concrete action needed to combat climate change: PM
  • COVID: Delhi reports 306 fatalities, 26,169 new cases; positivity rate swells to 36 24 pc
  • PM Modi cancels Bengal visit, to hold high level review meetings on COVID situation
  • CSIR-CMERI develops oxygen enrichment unit to combat nationwide oxygen supply shortage
  • Top 2 seeds in Men' Singles event, set up a summit clash at AITA Men's Open Tennis Tournament
  • TECNO ropes in Bollywood Superstar Ayushmann Khurrana as its Indian brand ambassador for 2021
  • EC prohibits road shows, pad-yatras, vehicle rallies for remaining two phases of West Bengal Assembly polls
  • COVID: HP sees 1,774 new cases, 18 die
  • Turnout around 80 per cent in sixth phase in Bengal
  • COVID-19: Karnataka reports 25,795 cases, highest single day hike
  • Out source employees to get incentive of Rs 200 per shift: CoM
  • PM cancels West Bengal tour
  • Sardar Patel Covid Care Centre at Chhatapur to reopen within 3 days
  • Foreign Ministers of Afghanistan, Pakistan, Turkey to meet in Istanbul: Ankara
  • UP adds 34,379 fresh Covid-19 cases, 195 deaths
Press Releases » Business Wire India


SMT Completes Enrolment of Cruz HBR Registry to Further Evaluate the Safety and Efficacy of Supraflex Cruz in High Bleeding Risk Patients

Business Wire India

Release summary points


  • 1200 {800 non-High Bleeding Risk (non-HBR) and 400 High Bleeding Risk (HBR) patients are involved in the registry}

  • 26 sites in 3 countries (France, Germany, Switzerland)



SMT (Sahajanand Medical Technologies Pvt. Ltd.), global manufacturer of cardiovascular medical devices, today announced that it has completed the patient enrolment for Cruz HBR Registry. Patient enrolment had started on February 19, 2020 and ended on October 16, 2020. The registry was conducted in France, Germany and Switzerland comprising of 26 sites.
 
This registry is a prospective, multi-center, single-arm registry to evaluate the safety and efficacy of Supraflex Cruz sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease by Percutaneous Coronary Intervention, to confirm the results from the TALENT trial in real life.
 
The secondary objective of this registry is to demonstrate that Supraflex Cruz stent is not inferior to BioFreedom™ stent amongst High Bleeding Risk patients. High bleeding risk patients are very complex set of population who are at a high risk of bleeding and high ischemic risk. The benefits of ultrathin Supraflex Cruz stent in this patient population will be evaluated for the first time in this study. The CRO for this study is Cardiovascular European Research Centre (CERC), France which carries a high reputation of conducting many landmark studies very successfully.
 
The study evaluates a total of 1200 patients amongst which 800 patients are having non-High Bleeding Risk and 400 patients possess bleeding risk factor. The study has been commenced under Principal Investigator and Senior Interventional Cardiologist Prof. Christoph Naber (Klinikum Wilhelmshaven), Germany.
 
Speaking more about the evaluation process, Principle Investigator Prof. Christoph Naber said, "I am sure the results of this registry will prove very useful for the colleagues out there in the Cath labs. While TALENT trial showed excellent data for the Supraflex family of Stent, Cruz HBR will extend our knowledge to all-comers and patients with high bleeding risk.”
 
Adding on the study front, the CEO of CERC, Dr Marie-Claude Morice said, "CERC team is very grateful to the Cruz HBR investigators, who recruited faster than expected all 1200 patients despite the Covid-19 period. Entire CERC team was mobilized to follow this rapid pace effectively."
 
Study pointers
Total No. of Patients: 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR)
Principal Investigator: Prof. Christoph Naber, Klinikum Wilhelmshaven, Germany
CRO: Cardiovascular European Research Center (CERC), France
Locations: 26 sites in 3 countries (France, Germany, Switzerland)
Study Start Date: February 19, 2020
 
The results of HBR Cruz Registry are expected by the end of year 2021.
 
BioFreedom™ is a polymer- and carrier-free Drug Coated Stent with BA9™ (DCS) by Biosensors International.
*Supraflex Cruz is a trademark of Sahajanand Medical Technologies Pvt. Ltd. or its affiliates.
More News
Wildermart Launches in India

Wildermart Launches in India

22 Apr 2021 | 8:03 PM

Wildermart Launches in India

see more..
GP Petroleums Under Its We Care CSR Initiative Organizes Health Checkup Camps Across 15 Cities

GP Petroleums Under Its We Care CSR Initiative Organizes Health Checkup Camps Across 15 Cities

22 Apr 2021 | 5:30 PM

GP Petroleums Under Its We Care CSR Initiative Organizes Health Checkup Camps Across 15 Cities

see more..

Wipro to reach Net-Zero Greenhouse Gas Emissions by 2040

22 Apr 2021 | 5:43 PM

Wipro to reach Net-Zero Greenhouse Gas Emissions by 2040

see more..

British Paints Says Nayi Umeedon Ke Rang Gungunaye with Their New Campaigns, Products, and Partner Empowerment Programs

22 Apr 2021 | 5:56 PM

British Paints Says Nayi Umeedon Ke Rang Gungunaye with Their New Campaigns, Products, and Partner Empowerment Programs

see more..

WNS Announces Fiscal 2021 Fourth Quarter and Full Year Earnings, Provides Guidance for Fiscal 2022

22 Apr 2021 | 3:30 PM

WNS Announces Fiscal 2021 Fourth Quarter and Full Year Earnings, Provides Guidance for Fiscal 2022

see more..
image